The CSL pattern, page-269

@LeonLevy: "CSL moving into gene therapy tells you the core business is under threat."

I'll bite seeing as I have nothing better to do at 5am odd. It doesn't tell me that, it tells me it's part of the fruits of spending over one billion a year on R&D (A$1.4 billion this year) so it doesn't have to rely on what you call it's core business. One area is gene therapy, there are plenty of others, CSL is not a one trick pony

Have a read of this: https://www.copyright link/companies/healthcare-and-fitness/csl-enters-ranks-of-world-s-biggest-biotechs-20200114-p53rbv

"For now... it has a strong pipeline coming through which should underpin investor confidence for the medium term.

The company has projects underway targeting a diverse array of conditions. These range from a gene therapy treatment for sickle cell anaemia to subarachnoid haemorrhage (bleeding in the brain following the rupture of an aneurysm) and prevention and treatment of graft-versus-host disease.One of the most advanced therapies in the pipeline is its CSL 112 therapy, which is a plasma-derived product it hopes could be used to prevent often deadly secondary heart attacks, which is currently in a phase three trial."

Anyway, as with Altium, which you also had concerns about being expensive, thanks for your input.